What impact does NICE’s modified Cancer Drugs Fund process mean for patient access to new oncology pharmaceuticals in England?

/, Publications/What impact does NICE’s modified Cancer Drugs Fund process mean for patient access to new oncology pharmaceuticals in England?

What impact does NICE’s modified Cancer Drugs Fund process mean for patient access to new oncology pharmaceuticals in England?

Remap Consulting recent analysis: “What impact does NICE’s modified Cancer Drugs Fund process mean for patient access to new oncology pharmaceuticals in England?” was presented at ISPOR’s 20th Annual European Congress in Glasgow.

In April 2016, NICE modified the Cancer Drugs Fund (CDF) appraisal process in England, to review all new oncology indications and publish final guidance within 90 days of marketing authorisation. Additionally, 14 existing legacy indications from the previous CDF had not undergone a NICE assessment and required review.

The new CDF has a fixed budget of £340m and treatments appraised under this process may; be recommended for routine use by NHS England; be retained in the CDF to gather additional evidence; not be recommended. In some cases, positive recommendations may be subject to confidential patient access schemes or restricted to specific patient populations.

This study investigates NICE evaluations of new cancer indications and of legacy CDF indications (not previously assessed by NICE), within the new CDF.

The full analysis can be found here: What impact does NICE’s modified Cancer Drugs Fund process mean for patient access to new oncology pharmaceuticals in England?

By |2018-06-08T09:41:12+00:00November 13th, 2017|News, Publications|0 Comments